Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

NCT05194124 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Bardet-Biedl Syndrome
POMC Deficiency

Interventions

DRUG: Setmelanotide 2 mg
DRUG: Setmelanotide 2.5 mg
DRUG: Setmelanotide 3 mg
DRUG: Setmelanotide 20 mg
DRUG: Setmelanotide 25 mg
DRUG: Setmelanotide 30 mg

Sponsor

Rhythm Pharmaceuticals, Inc.